Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. September 2015 07:05 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces Initiation of REGENERATE Trial for Obeticholic Acid in NASH Patients With Advanced Liver Fibrosis

NEW YORK, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
08. September 2015 07:05 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept to Present at the Baird Healthcare Conference

NEW YORK, Sept. 8, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
31. August 2015 07:05 ET | Quelle: Intercept Pharmaceuticals, Inc.

FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis

NEW YORK, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
05. August 2015 16:05 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Business Update

NEW YORK, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
29. Juli 2015 16:05 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept to Report Second Quarter 2015 Financial Results on August 5 and Present at Upcoming Conferences

NEW YORK, July 29, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
21. Juli 2015 16:05 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Appoints Richard Kim as Senior Vice President, Commercial Head of U.S.

NEW YORK, July 21, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
29. Juni 2015 16:05 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Submits Applications in the U.S. and Europe for Marketing Approval of Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis

NEW YORK, June 29, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
22. Juni 2015 06:00 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Appoints Juan Carlos Lopez-Talavera, M.D., Ph.D. as Senior Vice President of Medical Affairs

NEW YORK, June 22, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...
19. Mai 2015 06:00 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASH

-Key features of the REGENERATE Phase 3 trial in non-cirrhotic NASH with liver fibrosis finalized pursuant to consultations with FDA and EMA -REGENERATE trial design intended to support initial...
11. Mai 2015 06:01 ET | Quelle: Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Announces First Quarter 2015 Financial Results

NEW YORK, May 11, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...

Vorherige Seite